Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Concentration-controlled Everolimus to Eliminate or to Reduce Tacrolimus Compared to Tacrolimus in de Novo Liver Transplant Recipients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Ability and willingness to provide written informed consent and adhere to study regimen.~* Recipients who are 18-70 years of age of a primary liver transplant from a deceased donor.~* Recipients who have been initiated on an immunosuppressive regimen that contains corticosteroids and tacrolimus, 3-7 days post-transplantation.~* Confirmed recipient hepatitis C virus (HCV) status at Screening (either by antibody or by PCR (polymerase chain reaction).~* Allograft is functioning at an acceptable level by the time of randomization as defined by protocol specific laboratory values.~* Abbreviated Modification of Diet in Renal Disease estimated glomerular filtration rate (MDRD eGFR) ≥ 30 mL/min/1.73m2. Results obtained within 5 days prior to randomization are acceptable, however, no sooner than Day 25 post-transplantation.~* Verification of at least 1 tacrolimus trough level of ≥ 8 ng/mL in the week prior to randomization. Investigators should make adjustments in tacrolimus dosing to continue to target trough levels above 8 ng/mL prior to randomization.~Exclusion Criteria~* Patients who are recipients of multiple solid organ or islet cell tissue transplants, or have previously received an organ or tissue transplant. Patients who have a combined liver-kidney transplant.~* Recipients of a liver from a living donor, or of a split liver.~* History of malignancy of any organ system within the past 5 years whether or not there is evidence of local recurrence or metastases, other than non-metastatic basal or squamous cell carcinoma of the skin, or HCC (hepatocellular carcinoma) (see next criteria).~* Hepatocellular carcinoma that does not fulfill Milan criteria (1 nodule ≤ 5 cm, 2-3 nodules all \< 3 cm) at the time of transplantation as per explant histology of the recipient liver.~* Any use of antibody induction therapy.~* Patients with a known hypersensitivity to the drugs used on study or their class, or to any of the excipients.~* Patients who are recipients of ABO incompatible transplant grafts.~* Recipients of organs from donors who test positive for Hepatitis B surface antigen or HIV are excluded.~* Patients who have any surgical or medical condition, which in the opinion of the investigator, might significantly alter the absorption, distribution, metabolism and excretion of study drug.~* Women of child-bearing potential (WOCBP).~* Patients with any history of coagulopathy or medical condition requiring long-term anticoagulation which would preclude liver biopsy after transplantation. (Low dose aspirin treatment or interruption of chronic anticoagulant is allowed).~Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Everolimus + reduced tacrolimus (Type: EXPERIMENTAL): Low dose tacrolimus (tacrolimus reduced) + everolimus + corticosteroids.
- Tacrolimus elimination (Type: EXPERIMENTAL): Low-dose tacrolimus (until Month 4, then tacrolimus eliminated) + everolimus + corticosteroids.
- Tacrolimus control (Type: ACTIVE_COMPARATOR): Control dose tacrolimus + corticosteroids.

Based on this trial design, predict the completion outcome and termination type (if applicable).